How to Treat Gastrinomas in Patients with Multiple Endocrine Neoplasia Type1: Surgery or Long-term Proton Pump Inhibitors?

Overview

Journal Surg Today

Specialty General Surgery

Date 2022 Dec 6

PMID 36473964

Authors

Masayuki Imamura

Izumi Komoto

Yoshiro Taki

Affiliations

Soon will be listed here.

Abstract

In patients with multiple endocrine neoplasia type 1 syndrome (MEN 1) and Zollinger-Ellison syndrome (ZES), gastrinomas arise from the duodenum, about 60% are multiple, and about 15% of patients have coexisting pancreatic gastrinomas, which can be localized by the selective arterial secretagogue injection test (SASI test). The guidelines (GLs) by the Japanese Neuroendocrine Tumor Society (JNETS) recommend surgical resection for functioning duodenopancreatic neuroendocrine tumors (NETs), including gastrinomas, in patients with MEN1 (Grade A, 100% agreement among members). Conversely, the GLs of the National Comprehensive Cancer Network (NCCN) in the USA recommend observation and treatment with proton pump inhibitors (PPIs) or exploratory surgery for occult gastrinomas. An international Consensus Statement (ICS) from the European Union (EU) also does not recommend resection of gastrinomas in patients with MEN1, despite some surgeons having reported surgery being curative for gastrinomas in MEN1 patients. In this review, we discuss the serious side effects and tumorigenic effects of the prolonged use of PPIs and the safety and curability of surgery, supported by our results of curative surgery for gastrinomas in 20 patients with MEN1 over 30 years. We conclude that surgery should be the first-line treatment for gastrinomas in MEN1 patients.

Citing Articles

Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors.

Kenney L, Hughes M Cancers (Basel). 2025; 17(3).

PMID: 39941746 PMC: 11816225. DOI: 10.3390/cancers17030377.

Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.

Ito T, Ramos-Alvarez I, Jensen R Int J Mol Sci. 2024; 25(13).

PMID: 39000391 PMC: 11242121. DOI: 10.3390/ijms25137286.

Sporadic Zollinger-Ellison syndrome in a patient with isolated mesenteric gastrinoma.

Efared B, Tassiou E, Bako A, Boubacar I, Boureima H, Nouhou H Int J Surg Case Rep. 2024; 116:109474.

PMID: 38447521 PMC: 10926117. DOI: 10.1016/j.ijscr.2024.109474.

Typical Zollinger-Ellison syndrome-atypical location of gastrinoma and absence of hypergastrinemia: A case report and review of literature.

Zhang J, Zheng C, Li X, Fang Z, Yu M, Shen H World J Clin Cases. 2023; 11(26):6223-6230.

PMID: 37731553 PMC: 10507545. DOI: 10.12998/wjcc.v11.i26.6223.

Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES.

Ito T, Ramos-Alvarez I, Jensen R Cancers (Basel). 2023; 15(5).

PMID: 36900170 PMC: 10000208. DOI: 10.3390/cancers15051377.

References

Norton J, Melcher M, Gibril F, Jensen R . Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2005; 136(6):1267-74. DOI: 10.1016/j.surg.2004.06.057. View

Ito T, Masui T, Komoto I, Doi R, Osamura R, Sakurai A . JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol. 2021; 56(11):1033-1044. PMC: 8531106. DOI: 10.1007/s00535-021-01827-7. View

Kato M, Imamura M, Hosotani R, Shimada Y, Doi R, Itami A . Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg. 2000; 24(11):1425-30. DOI: 10.1007/s002680010235. View

Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M . Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987; 205(3):230-9. PMC: 1492726. DOI: 10.1097/00000658-198703000-00003. View

Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop A . Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990; 322(11):723-7. DOI: 10.1056/NEJM199003153221103. View

ZOLLINGER R, ELLISON E . Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955; 142(4):709-23; discussion, 724-8. PMC: 1465210. View

Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas P . Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015; 42(6):649-63. DOI: 10.1111/apt.13324. View

Bakke I, Qvigstad G, Brenna E, Sandvik A, Waldum H . Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand. 2000; 169(1):29-37. DOI: 10.1046/j.1365-201x.2000.00688.x. View

Epstein M, McGrath S, Law F . Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355(17):1834-6. DOI: 10.1056/NEJMc066308. View

10.

Norton J, Fraker D, Alexander H, Gibril F, Liewehr D, Venzon D . Surgery increases survival in patients with gastrinoma. Ann Surg. 2006; 244(3):410-9. PMC: 1856542. DOI: 10.1097/01.sla.0000234802.44320.a5. View

11.

Vogel S, Wolfe M, McGuigan J, Hawkins Jr I, Howard R, WOODWARD E . Localization and resection of gastrinomas in Zollinger-Ellison syndrome. Ann Surg. 1987; 205(5):550-6. PMC: 1493021. DOI: 10.1097/00000658-198705000-00014. View

12.

Ingemansson S, Larsson L, Lunderquist A, Stadil F . Pancreatic vein catheterization with gastrin assay in normal patients and in patients with the Zollinger-Ellison syndrome. Am J Surg. 1977; 134(5):558-63. DOI: 10.1016/0002-9610(77)90433-0. View

13.

Chung R, Church J, vanStolk R . Pancreas-sparing duodenectomy: indications, surgical technique, and results. Surgery. 1995; 117(3):254-9. DOI: 10.1016/s0039-6060(05)80198-9. View

14.

Anlauf M, Garbrecht N, Henopp T, Schmitt A, Schlenger R, Raffel A . Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006; 12(34):5440-6. PMC: 4088224. DOI: 10.3748/wjg.v12.i34.5440. View

15.

Lopez C, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki P . Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg. 2012; 257(2):308-14. DOI: 10.1097/SLA.0b013e3182536339. View

16.

Imamura M, Komoto I, Ota S, Hiratsuka T, Kosugi S, Doi R . Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol. 2011; 17(10):1343-53. PMC: 3068271. DOI: 10.3748/wjg.v17.i10.1343. View

17.

Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, Ebeling P . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9):2990-3011. DOI: 10.1210/jc.2012-1230. View

18.

Imamura M, Takahashi K, Isobe Y, Hattori Y, Satomura K, Tobe T . Curative resection of multiple gastrinomas aided by selective arterial secretin injection test and intraoperative secretin test. Ann Surg. 1989; 210(6):710-8. PMC: 1357861. DOI: 10.1097/00000658-198912000-00004. View

19.

Doppman J, Miller D, Chang R, Maton P, London J, Gardner J . Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990; 174(1):25-9. DOI: 10.1148/radiology.174.1.2294556. View

20.

Luk C, Parsons R, Lee Y, Hughes J . Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us?. Ann Pharmacother. 2013; 47(6):773-80. DOI: 10.1345/aph.1R556. View